0.7599
price up icon6.34%   0.0453
after-market 시간 외 거래: .73 -0.0299 -3.93%
loading
전일 마감가:
$0.7146
열려 있는:
$0.7045
하루 거래량:
631.79K
Relative Volume:
0.73
시가총액:
$31.19M
수익:
-
순이익/손실:
$-31.11M
주가수익비율:
-0.4967
EPS:
-1.53
순현금흐름:
$-28.18M
1주 성능:
-5.15%
1개월 성능:
-6.12%
6개월 성능:
-43.29%
1년 성능:
-85.07%
1일 변동 폭
Value
$0.70
$0.7599
1주일 범위
Value
$0.70
$0.84
52주 변동 폭
Value
$0.6986
$5.33

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name
명칭
Tempest Therapeutics Inc
Name
전화
415-798-8589
Name
주소
2000 SIERRA POINT PARKWAY, BRISBANE
Name
직원
17
Name
트위터
Name
다음 수익 날짜
2025-03-26
Name
최신 SEC 제출 서류
Name
TPST's Discussions on Twitter

TPST을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
TPST
Tempest Therapeutics Inc
0.7599 31.19M 0 -31.11M -28.18M -1.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-03-14 개시 Scotiabank Sector Outperform
2024-02-08 개시 Jefferies Buy

Tempest Therapeutics Inc 주식(TPST)의 최신 뉴스

pulisher
05:14 AM

Virtu Financial LLC Purchases Shares of 43,105 Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

05:14 AM
pulisher
Mar 31, 2025

FY2028 Earnings Estimate for TPST Issued By William Blair - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Estimate for TPST Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Scotiabank Has Lowered Expectations for Tempest Therapeutics (NASDAQ:TPST) Stock Price - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Scotiabank Lowers Tempest Therapeutics (NASDAQ:TPST) Price Target to $7.00 - Armenian Reporter

Mar 30, 2025
pulisher
Mar 30, 2025

HC Wainwright Has Lowered Expectations for Tempest Therapeutics (NASDAQ:TPST) Stock Price - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Tempest Therapeutics Advances Cancer Therapies Amid Financial Challenges - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

H.C. Wainwright cuts Tempest Therapeutics stock target to $16 By Investing.com - Investing.com UK

Mar 28, 2025
pulisher
Mar 27, 2025

Tempest Therapeutics Inc. (TPST) reports earnings - Quartz

Mar 27, 2025
pulisher
Mar 27, 2025

Why Super Micro Computer Stock Was Sliding This Week - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

Tempest Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Tempest's Cancer Drug Shows 6-Month Survival Gain, Lands Major Roche Partnership - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

Tempest Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView

Mar 26, 2025
pulisher
Mar 25, 2025

Tempest Announces Amezalpat Poster Presentation at the 2025 - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Breakthrough Cancer Drug Data Reveals New Immune Response Findings at AACR 2025 - Stock Titan

Mar 25, 2025
pulisher
Mar 13, 2025

Tempest Therapeutics advances Phase 2 trial for cancer prevention By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

FDA Study May Proceed Notice Received for Phase 2 Trial of - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Tempest Therapeutics Says Familial Adenomatous Polyposis Trial Gets US FDA 'Study May Proceed' Notice - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

Tempest Therapeutics advances Phase 2 trial for cancer prevention - Investing.com India

Mar 13, 2025
pulisher
Mar 13, 2025

Tempest gets FDA nod to begin mid-stage study of its therapy for colon cancer-causing genertic condition - Marketscreener.com

Mar 13, 2025
pulisher
Mar 13, 2025

FDA Green Light: Tempest's Revolutionary FAP Drug Advances to Phase 2 with NCI Backing - StockTitan

Mar 13, 2025
pulisher
Mar 11, 2025

Tempest Therapeutics (TPST) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Mar 11, 2025
pulisher
Mar 07, 2025

Tempest Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:TPST - Benzinga

Mar 07, 2025
pulisher
Mar 01, 2025

Comparing Tempest Therapeutics (NASDAQ:TPST) & Nkarta (NASDAQ:NKTX) - Defense World

Mar 01, 2025
pulisher
Feb 17, 2025

Tempest Therapeutics, Inc. (NASDAQ:TPST) Sees Significant Decrease in Short Interest - Defense World

Feb 17, 2025
pulisher
Feb 11, 2025

TPST stock rated a Sector outperform by Scotiabank - Knox Daily

Feb 11, 2025
pulisher
Feb 11, 2025

Tempest gets fast track designation from FDA for amezalpat - MSN

Feb 11, 2025
pulisher
Feb 11, 2025

A closer look at Tempest Therapeutics Inc (TPST)’s stock price trends - US Post News

Feb 11, 2025
pulisher
Feb 11, 2025

Tempest Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation to Amezalpat (TPST-1120) - Marketscreener.com

Feb 11, 2025
pulisher
Feb 10, 2025

Tempest Therapeutics Inc (TPST) Shares Rise Despite Market Challenges - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

Tempest Therapeutics Says Amezalpat Receives US FDA Fast Track Status As Treatment for Liver Cancer - Marketscreener.com

Feb 10, 2025
pulisher
Feb 10, 2025

Tempest Granted Fast Track Designation From The U.S. Food And Drug Administration For Amezalpat - Marketscreener.com

Feb 10, 2025
pulisher
Feb 10, 2025

Tempest Granted Fast Track Designation from the U.S. Food - GlobeNewswire

Feb 10, 2025
pulisher
Feb 10, 2025

Tempest's Liver Cancer Breakthrough: FDA Fast-Tracks Drug Showing 6-Month Survival Gain - Stock Titan

Feb 10, 2025
pulisher
Feb 07, 2025

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 07, 2025
pulisher
Feb 07, 2025

Tempest Therapeutics Awards Strategic Compensation Package: Inside the 4-Year Vesting Deal - StockTitan

Feb 07, 2025
pulisher
Feb 04, 2025

Analyzing Ratios: Tempest Therapeutics Inc (TPST)’s Financial Story Unveiled - The Dwinnex

Feb 04, 2025
pulisher
Feb 04, 2025

A stock that deserves closer examination: Tempest Therapeutics Inc (TPST) - US Post News

Feb 04, 2025
pulisher
Jan 27, 2025

Tempest Therapeutics Inc (NASDAQ: TPST) – An Analysis Is What You Need - Stocks Register

Jan 27, 2025
pulisher
Jan 14, 2025

Tempest Therapeutics, Inc. (NASDAQ:TPST) Shares Acquired by Geode Capital Management LLC - Defense World

Jan 14, 2025
pulisher
Jan 06, 2025

Tempest Receives Orphan Drug Designation from the U.S. Food - GlobeNewswire

Jan 06, 2025
pulisher
Jan 06, 2025

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) - GlobeNewswire Inc.

Jan 06, 2025
pulisher
Jan 02, 2025

Before You Sell Tempest Therapeutics Inc (NASDAQ: TPST) Shares, Here’sWhat You Need To Know. - Stocks Register

Jan 02, 2025
pulisher
Dec 30, 2024

Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register

Dec 30, 2024
pulisher
Dec 14, 2024

TPST Stock Touches 52-Week Low at $0.8 Amid Market Challenges - Investing.com Canada

Dec 14, 2024
pulisher
Dec 13, 2024

TPST Stock Touches 52-Week Low at $0.8 Amid Market Challenges By Investing.com - Investing.com South Africa

Dec 13, 2024
pulisher
Dec 10, 2024

Thinking about buying stock in Nikola, Delcath Systems, Taysha G - GuruFocus.com

Dec 10, 2024
pulisher
Dec 06, 2024

Tempest Therapeutics amends rights agreement By Investing.com - Investing.com Australia

Dec 06, 2024
pulisher
Dec 06, 2024

Tempest Therapeutics amends rights agreement - Investing.com India

Dec 06, 2024
pulisher
Dec 06, 2024

Tempest Therapeutics Awards Key Employee Stock Options in Strategic Compensation Move | TPST Stock News - StockTitan

Dec 06, 2024
pulisher
Nov 27, 2024

Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock - Yahoo Finance

Nov 27, 2024

Tempest Therapeutics Inc (TPST) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
자본화:     |  볼륨(24시간):